Premium
Erectile function status is highly associated with prostate‐specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy
Author(s) -
Matsushima Masashi,
Kikuchi Eiji,
Matsumoto Kazuhiro,
Kosaka Takeo,
Mizuno Ryuichi,
Ohashi Toshio,
Mikami Shuji,
Miyajima Akira,
Shigematsu Naoyuki,
Oya Mototsugu
Publication year - 2016
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.13029
Subject(s) - brachytherapy , medicine , prostate cancer , urology , prostate specific antigen , prostate , erectile function , erectile dysfunction , prostate brachytherapy , logistic regression , international prostate symptom score , oncology , cancer , radiation therapy , lower urinary tract symptoms
Objectives To examine the relationship between erectile function status and prostate‐specific antigen bounce after prostate brachytherapy for localized prostate cancer. Methods We identified 154 patients who were followed up for at least 24 months after brachytherapy. Erectile function status was assessed prospectively before brachytherapy (baseline), and 3, 6, 12, 18, 24 and 36 months postoperatively using the International Index of Erectile Function‐15 questionnaire. Prostate‐specific antigen bounce was defined as an increase of at least 0.4 ng/mL from a previous prostate‐specific antigen level with a subsequent decline equal to, or less than, the initial nadir without treatment. A logistic regression analysis was used to identify a significant set of independent predictors of prostate‐specific antigen bounce after brachytherapy. Results Prostate‐specific antigen bounce was observed in 38 (24.7%) men. The prostate‐specific antigen bounce group had a higher erectile function domain score, higher orgasmic function domain score, and higher total International Index of Erectile Function‐15 score before (at baseline) and after brachytherapy (3, 6, 12, 18, 24 and 36 months after brachytherapy) than their counterparts ( P < 0.05). Of the 77 patients who completed the International Index of Erectile Function‐15 questionnaire 18 months after brachytherapy (the median time of prostate‐specific antigen bounce), sexual desire and intercourse satisfaction domain scores, and total International Index of Erectile Function scores 18 months after brachytherapy correlated with the occurrence of prostate‐specific antigen bounce. A multivariate analysis identified the intercourse satisfaction domain score 18 months after brachytherapy as an independent indicator for the occurrence of prostate‐specific antigen bounce ( P = 0.008). Conclusions International Index of Erectile Function‐15 score seems to be correlated with the prostate‐specific antigen bounce in prostate cancer patients undergoing brachytherapy, and an occurrence of prostate‐specific antigen bounce seems to be more likely in those who are more sexually active.